Poly(ADP-ribose) Polymerase Inhibitors

Chemicals and drugs that inhibit the action of POLY(ADP-RIBOSE)POLYMERASES.

Also Known As:

Inhibitors of Poly(ADP-ribose) Polymerases; PARP Inhibitors; Poly(ADP-ribosylation) Inhibitors; Inhibitor, PARP; Inhibitors, PARP; Inhibitors of Poly(ADP-ribose) Polymerase; PARP Inhibitor; Poly(ADP-Ribose) Polymerase Inhibitor; Poly(ADP-ribosylation) Inhibitor

Networked: 4059 relevant articles (430 outcomes, 765 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Therapeutic Uses: 47080
    - Antineoplastic Agents: 20689
      - Poly(ADP-ribose) Polymerase Inhibitors: 4059
  - Molecular Mechanisms of Pharmacological Action: 24
    - Enzyme Inhibitors: 1659
      - Poly(ADP-ribose) Polymerase Inhibitors: 4059

Experts

1.	Lord, Christopher J: 43 articles (11/2022 - 09/2005)
2.	Swisher, Elizabeth M: 36 articles (01/2022 - 04/2011)
3.	Ashworth, Alan: 34 articles (01/2021 - 09/2005)
4.	O'Connor, Mark J: 33 articles (01/2022 - 06/2008)
5.	Coleman, Robert L: 32 articles (03/2022 - 06/2015)
6.	Oza, Amit M: 31 articles (01/2022 - 10/2013)
7.	Szabó, Csaba: 31 articles (01/2018 - 01/2002)
8.	Jonkers, Jos: 29 articles (12/2021 - 06/2008)
9.	Kaufmann, Scott H: 28 articles (01/2022 - 02/2011)
10.	Matulonis, Ursula A: 25 articles (07/2022 - 09/2013)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2021 - "Poly ADP ribose polymerase inhibitors (PARPi) are most effective in BRCA1/2 mutated ovarian tumors. " 11/30/2020 - "Inhibitors of poly-ADP-ribose polymerase 1 (PARPi) are highly effective in killing cells deficient in homologous recombination (HR); thus, PARPi have been clinically utilized to successfully treat BRCA2-mutant tumors. " 11/19/2020 - "PARP inhibitors have shown remarkable efficacy in the clinical management of several BRCA-mutated tumors. " 01/01/2020 - "Development of these radiolabeled PARP inhibitors has presented promising results for new interventions in the fight against some of the most intractable cancers." 01/01/2019 - "PARP inhibitors (PARPi) have shown remarkable therapeutic efficacy against BRCA1/2-mutant cancers through a synthetic lethal interaction. "
2.	Ovarian Neoplasms (Ovarian Cancer) 04/01/2022 - "PARP inhibitors have dramatically improved outcomes for ovarian cancer patients, transforming oncologists' armamentarium and fueling hope for more cures and longer survival. " 03/01/2020 - "PARP inhibitors (PARPi) have drawn increasing amount of attention due to their remarkable efficacy and low toxicity in treating HR-deficient ovarian cancers (i.e. " 01/07/2023 - "PARP inhibitors have been approved for the treatment of ovarian cancer for several years and achieved good results. " 08/13/2022 - "Treatment with PARP inhibitors (PARPi) is primarily effective against high-grade serous ovarian cancers (HGSOC) with BRCA1/2 mutations or other deficiencies in homologous recombination (HR) repair mechanisms. " 11/01/2021 - "Poly(ADP-ribose) polymerase inhibitors (PARPi) are FDA approved as frontline maintenance for BRCA-associated advanced stage high-grade ovarian cancer (HGOC), having demonstrated an unprecedented improvement in relapse-free survival. "
3.	Breast Neoplasms (Breast Cancer) 12/01/2021 - "The results showed that progression-free survival (PFS) and overall survival (OS) were significantly improved in germline BRCA-mutated breast cancer patients with PARP inhibitors (HR 0.64, 95% CI [0.56-0.74]; HR 0.86, 95% CI [0.74-0.99], respectively) with no significant heterogeneity across studies (I2 = 22%, χ2 p = 0.28; I2 = 0%, χ2 p = 0.70, respectively). " 04/22/2021 - "High-certainty evidence shows that PARP inhibitors offer an improvement in PFS in locally advanced/metastatic HER2-negative, BRCA germline mutated breast cancer patients (HR 0.63, 95% CI 0.56 to 0.71; 5 studies; 1474 patients). " 04/22/2021 - "In people with locally advanced or metastatic HER2-negative, BRCA germline mutated breast cancer, PARP inhibitors offer an improvement in progression-free survival, and likely improve overall survival and tumour response rates. " 09/01/2009 - "PARP inhibitors are now showing considerable promise in the clinic, specifically in patients with mutations in either of the breast cancer susceptibility genes BRCA1 or BRCA2. " 02/01/2021 - "Previous clinical trials demonstrated the therapeutic efficacy of poly (ADP-ribose) polymerase inhibitors (PARPis) against BRCA-mutated metastatic breast cancer. "
4.	Prostatic Neoplasms (Prostate Cancer) 11/01/2021 - "Monotherapy with PARP inhibitors is effective for the subset of castrate-resistant prostate cancer (CRPC) with defects in homologous recombination (HR) DNA repair. " 05/09/2017 - "Moreover, we tested the efficacy of the USP7 inhibitors, in combination with PARP-inhibitors as a novel therapeutic option in advanced prostate cancer.Experimental" 08/23/2023 - "Triggering pyroptosis enhances the antitumor efficacy of PARP inhibitors in prostate cancer." 01/01/2022 - "Focusing on known pathogenic alterations within homologous recombination repair genes, we find 10 patients (19.6%) fulfilling the inclusion criteria used in the PROfound clinical trial, which assessed the efficacy of PARP inhibitors (PARPi) in homologous recombination deficient prostate cancer. " 10/09/2023 - "Hematological Toxicities with PARP Inhibitors in Prostate Cancer: A Systematic Review and Meta-Analysis of Phase II/III Randomized Controlled Trials."
5.	Triple Negative Breast Neoplasms 12/28/2022 - "Poly ADP-ribose polymerase inhibitor (PARPi) treatment is effective in triple-negative breast cancer (TNBC) with BRCA mutation. " 11/01/2019 - "Poly ADP-ribose polymerase inhibitors (PARPi) have shown promising therapeutic efficacy in triple-negative breast cancer (TNBC) patients. " 01/01/2014 - "Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness." 01/01/2021 - "Preclinical studies have evidenced that triple-negative breast cancer (TNBC) cell lines are more sensitive to poly (ADP-ribose) polymerase inhibitors. " 10/01/2010 - "This hypothesis has borne out in both preclinical models and in clinical trials testing PARP inhibitors in both BRCA-deficient and triple-negative breast cancer. "

Related Drugs and Biologics

1.	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)
2.	olaparib
3.	Platinum
4.	rucaparib
5.	Bevacizumab (Avastin)
6.	DNA (Deoxyribonucleic Acid)
7.	veliparib
8.	Poly(ADP-ribose) Polymerase Inhibitors
9.	talazoparib
10.	Carboplatin (JM8)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Castration
4.	Immunotherapy
5.	Radiotherapy